Document Detail


Evidence-based management of ANCA vasculitis.
MedLine Citation:
PMID:  19508944     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The vasculitides associated with antineutrophil cytoplasmic antibodies (ANCAs) present to and are managed by a wide spectrum of physicians, reflecting the multi-organ nature of the conditions. Treatment strategies for these primary inflammatory vascular diseases have varied based on the outcomes of different clinical trials and practice reviews. The individual drugs used and their route of administration, dose, and duration of therapy have varied and have been the source of much debate. Advances in our understanding of disease immunopathogenesis, clinical assessment and outcome have formed the basis for several recent good-quality clinical trials. Now, with the results of these large-scale multicentre collaborative studies, there is a firmer evidence base to guide management decisions for individual patients. This evidence base, reviewed here, has led to the publication of treatment guidelines which importantly encompass many of the broader aspects of disease management.
Authors:
David Carruthers; Jonathan Sherlock
Related Documents :
19583554 - Evidence-based medicine and the cochrane collaboration.
16533454 - Controversy in colposcopic management: a canadian survey.
9839634 - Evidence and clinical judgement.
19780934 - A survey of evidence in the journal of veterinary internal medicine oncology manuscript...
8285084 - Assessing bad debt in new hampshire and vermont office-based practices.
20637464 - Parents' self-efficacy, outcome expectations, and self-reported task performance when m...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Best practice & research. Clinical rheumatology     Volume:  23     ISSN:  1532-1770     ISO Abbreviation:  Best Pract Res Clin Rheumatol     Publication Date:  2009 Jun 
Date Detail:
Created Date:  2009-06-10     Completed Date:  2009-08-27     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101121149     Medline TA:  Best Pract Res Clin Rheumatol     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  367-78     Citation Subset:  IM    
Affiliation:
Department of Rheumatology, City Hospital, Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, UK. david.carruthers@swbh.nhs.uk
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antibodies, Antineutrophil Cytoplasmic / immunology*
Clinical Trials as Topic
Cyclophosphamide / therapeutic use
Drug Therapy, Combination
Evidence-Based Medicine
Humans
Immunosuppressive Agents / therapeutic use*
Methotrexate / therapeutic use
Practice Guidelines as Topic
Remission Induction
Vasculitis / immunology*,  therapy*
Wegener Granulomatosis
Chemical
Reg. No./Substance:
0/Antibodies, Antineutrophil Cytoplasmic; 0/Immunosuppressive Agents; 50-18-0/Cyclophosphamide; 59-05-2/Methotrexate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Churg-Strauss angiitis.
Next Document:  Newer therapies for vasculitis.